Basel, 3 May 2012
Roche Analyst Event at ASCO 2012
Analyst briefing on data presented at ASCO: Sunday, 3 June 2012
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (June 1-5, 2012).
Marriott Downtown Chicago
540 North Michigan Avenue
Sunday, 3 June 2012
6:30pm to 8:00pm Central Daylight Time CDT (Chicago)
followed by a buffet reception
- Trastuzumab emtansine (T-DM1) in HER2-positive locally advanced or metastatic breast cancer, EMILIA study
- Oncology pipeline update
- Oncology business and strategy update
3 June 2012
6:00pm CDTRegistration desk opens
6:30pm CDTStart of meeting
8:00pm CDTEnd of meeting followed by a buffet reception
To register for the event, please follow the link.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.